DIAMOND

Mark For: DIAMOND™ trademark registration is intended to cover the categories of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of neurological diseases and disorders, central nervous system diseases and disorders, neurodegenerative diseases and disorders, immune system-related diseases and disorders, and metabolic diseases and disorders; software for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and transmission of data, images, information and artificial intelligence in the fields of drug discovery and healthcare, biomedical and genomic research; software featuring machine learning and artificial intelligence for data analysis in the fields of drug discovery and healthcare, biomedical and genomic research; software featuring machine learning and artificial intelligence for drug analysis in drug discovery and development; software incorporating artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks; software for genetic assessment and identification of cancer, diseases, health status and metrics, and gene mutations for scientific, medical, diagnostic, treatment, and research purposes; software for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; software for collecting, analyzing, reporting, and tracking data and information in the fields of clinical trial management and patient engagement; scientific research, namely, research and analysis services featuring artificial intelligence and machine learning analytics in the fields of healthcare, biomedical and genomic research; research and development in the field of drug discovery and development, computational biology, bioinformatics, and genomics; research and development of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of neurological diseases and disorders, central nervous system diseases and disorders, neurodegenerative diseases and disorders, immune system-related diseases and disorders, and metabolic diseases and disorders; technical scientific consultation and product development for others in the fields of drug discovery and development, pharmaceuticals, biotechnology and immunology; consulting in the fields of drug discovery and development, clinical trial management and patient engagement in drug clinical trials. [all]

Status

2022-01-23 UTC
⟳ Refresh

LIVE APPLICATION Awaiting Examination

Research	OneLook Acronym Finder
Serial Number	97220299
Mark Literal Elements	DIAMOND
Mark Drawing Type	4 - STANDARD CHARACTER MARK
Mark Type	SERVICE MARK
Register	PRINCIPAL
Current Location	NEW APPLICATION PROCESSING 2022-01-21
Basis	1(b)
Class Status	ACTIVE
Primary US Classes	100: Miscellaneous 101: Advertising and Business
Primary International Class	044 - Primary Class (Medical, beauty & agricultural) Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
Filed Use	No
Current Use	No
Intent To Use	Yes
Filed ITU	Yes
44D Filed	No
44E Current	No
66A Current	No
Current Basis	No
No Basis	No
Attorney Name	Christina M. Licursi
Attorney Docket Number	F08472000300

Timeline

IC 044. US 100 101. G & S: Pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of neurological diseases and disorders, central nervous system diseases and disorders, neurodegenerative diseases and disorders, immune system-related diseases and disorders, and metabolic diseases and disorders; software for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and transmission of data, images, information and artificial intelligence in the fields of drug discovery and healthcare, biomedical and genomic research; software featuring machine learning and artificial intelligence for data analysis in the fields of drug discovery and healthcare, biomedical and genomic research; software featuring machine learning and artificial intelligence for drug analysis in drug discovery and development; software incorporating artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks; software for genetic assessment and identification of cancer, diseases, health status and metrics, and gene mutations for scientific, medical, diagnostic, treatment, and research purposes; software for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; software for collecting, analyzing, reporting, and tracking data and information in the fields of clinical trial management and patient engagement; scientific research, namely, research and analysis services featuring artificial intelligence and machine learning analytics in the fields of healthcare, biomedical and genomic research; research and development in the field of drug discovery and development, computational biology, bioinformatics, and genomics; research and development of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of neurological diseases and disorders, central nervous system diseases and disorders, neurodegenerative diseases and disorders, immune system-related diseases and disorders, and metabolic diseases and disorders; technical scientific consultation and product development for others in the fields of drug discovery and development, pharmaceuticals, biotechnology and immunology; consulting in the fields of drug discovery and development, clinical trial management and patient engagement in drug clinical trials